早期肺鳞状细胞癌的突变谱及其与临床随访和免疫标志物的相关性
该研究对108对手术切除的I-III期肺鳞状细胞癌(LUSC)与正常肺组织行全外显子测序,并对91例LUSC行10种免疫标志物的免疫组化与图像分析。发现14个基因体细胞突变显著富集,MLL2突变在TP53突变型与野生型中均预示预后不良,FBXW7与KEAP1突变与辅助治疗反应差相关,ADCY8与PIK3CA突变与肿瘤PD-L1表达降低相关。
要点
- 早期LUSC每肿瘤平均209个外显子突变,14个基因突变显著富集。
- MLL2突变在TP53突变型和野生型LUSC中均预示无复发生存期差。
- FBXW7和KEAP1突变与辅助治疗反应差相关,尤其在TP53突变肿瘤中。
核心结论
- 研究定位了可能影响早期LUSC临床结局的突变基因,并可能为个体化靶向免疫治疗策略提供依据。
研究设计与样本
- 对108对手术切除的I-III期LUSC与正常肺组织行全外显子测序。
- 对91例LUSC子集行10种免疫标志物的免疫组化与图像分析。
- 使用方差分析和Fisher精确检验分析突变、免疫标志物与临床病理变量的关联,采用Cox比例风险回归模型分析临床结局。
主要发现
- 该早期LUSC队列每肿瘤平均209个外显子突变。
- 14个基因体细胞突变显著富集:TP53、MLL2、PIK3CA、NFE2L2、CDH8、KEAP1、PTEN、ADCY8、PTPRT、CALCR、GRM8、FBXW7、RB1和CDKN2A。
- MLL2突变在TP53突变型和野生型LUSC中均预示预后不良。
- 在接受治疗的患者中,FBXW7和KEAP1突变与辅助治疗反应差相关,尤其在TP53突变肿瘤中。
- ADCY8和PIK3CA突变与肿瘤PD-L1表达显著降低相关,PIK3CA突变LUSC的CD45ro水平升高,CDKN2A突变肿瘤显示免疫反应上调。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lung squamous cell carcinoma (LUSC) accounts for 20–30% of non-small cell lung cancers (NSCLCs). There are limited treatment strategies for LUSC in part due to our inadequate understanding of the molecular underpinnings of the disease. We performed whole-exome sequencing (WES) and comprehensive immune profiling of a unique set of clinically annotated early-stage LUSCs to increase our understanding of the pathobiology of this malignancy. METHODS: Matched pairs of surgically resected stage I-III LUSCs and normal lung tissues (n = 108) were analyzed by WES. Immunohistochemistry and image analysis-based profiling of 10 immune markers were done on a subset of LUSCs (n = 91). Associations among mutations, immune markers and clinicopathological variables were statistically examined using analysis of variance and Fisher’s exact test. Cox proportional hazards regression models were used for statistical analysis of clinical outcome. RESULTS: This early-stage LUSC cohort displayed an average of 209 exonic mutations per tumor. Fourteen genes exhibited significant enrichment for somatic mutation: TP53, MLL2, PIK3CA, NFE2L2, CDH8, KEAP1, PTEN, ADCY8, PTPRT, CALCR, GRM8, FBXW7, RB1 and CDKN2A. Among mutated genes associated with poor recurrence-free survival, MLL2 mutations predicted poor prognosis in both TP53 mutant and wild-type LUSCs. We also found that in treated patients, FBXW7 and KEAP1 mutations were associated with poor response to adjuvant therapy, particularly in TP53-mutant tumors. Analysis of mutations with immune markers revealed that ADCY8 and PIK3CA mutations were associated with markedly decreased tumoral PD-L1 expression, LUSCs with PIK3CA mutations exhibited elevated CD45ro levels and CDKN2A-mutant tumors displayed an up-regulated immune response. CONCLUSION(S): Our findings pinpoint mutated genes that may impact clinical outcome as well as personalized strategies for targeted immunotherapies in early-stage LUSC.
引用
- Choi M, Kadara H, Zhang J, et al. Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function. Ann Oncol. 2017. PMID: 28177435. doi:10.1093/annonc/mdw437
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。